TheraRadar
Home/Indications/Generalized Tonic-Clonic Seizures

Generalized Tonic-Clonic Seizures

0 original drugs
0
Novel Drugs
13
Reformulations
0
Active Trials
6
Drug Targets

Generalized Tonic-Clonic Seizures has 0 FDA-approved novel treatments across 6 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Phase 3 Readouts Pro

1 active Phase 3 trial with confidence-graded completion dates.

Full calendar →
Q2 2027
XEN1101
Xenon Pharmaceuticals Inc.
Estimated · fresh NCT05667142

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Generalized Tonic-Clonic Seizures Treatments by Mechanism

Top 2 mechanisms across 5 industry trials with a known mechanism of action.

See full pipeline →
SV2A
3 trials 2 sponsors
Noncompetitive AMPA Glutamate Receptor Antagonist
2 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Generalized Tonic-Clonic Seizures Clinical Pipeline by Phase

6 industry-sponsored trials across 4 sponsors

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Generalized Tonic-Clonic Seizures

Novel Generalized Tonic-Clonic Seizures Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (13 drugs) Click to expand

Generalized Tonic-Clonic Seizures Drug Targets

Molecular targets of approved and investigational Generalized Tonic-Clonic Seizures drugs — 6 targets tracked.

Generic Drugs (5 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

Drug Categories:

  • Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
  • Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
  • Biosimilars: BLA-approved biologics highly similar to reference products
  • Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology